FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1988637640> ?p ?o ?g. }

• W1988637640 abstract "You have accessJournal of UrologyBladder Cancer: Invasive II1 Apr 2014MP55-04 PARTIAL CYSTECTOMY POST NEOADJUVANT CHEMOTHERAPY: MEMORIAL SLOAN-KETTERING CANCER CENTER CONTEMPORARY EXPERIENCE Wassim Bazzi, Ryan Kopp, Timothy Donahue, Melanie Bernstein, Paul Russo, Bernard Bochner, Sherri Donat, Guido Dalbagni, and Harry Herr Wassim BazziWassim Bazzi More articles by this author , Ryan KoppRyan Kopp More articles by this author , Timothy DonahueTimothy Donahue More articles by this author , Melanie BernsteinMelanie Bernstein More articles by this author , Paul RussoPaul Russo More articles by this author , Bernard BochnerBernard Bochner More articles by this author , Sherri DonatSherri Donat More articles by this author , Guido DalbagniGuido Dalbagni More articles by this author , and Harry HerrHarry Herr More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.1552AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail Introduction and Objectives Partial cystectomy (PC) results in similar oncologic outcomes compared to radical cystectomy (RC) for selected patients while preserving quality of life. We report our experience with PC post-neoadjuvant chemotherapy (NC). Methods IRB approved review of patients treated with NC and PC for bladder urothelial cell carcinoma at Memorial Sloan-Kettering Cancer Center from 1995 to 2013. Variables included age, gender, race, tumor size, focality, histology, presence of carcinoma in situ (CIS), NC, clinical and pathologic stages, surgical margins (SM), disease status, and cause of death. We analyzed variables for association with recurrence free survival (RFS - defined as any recurrence), advanced recurrence free survival (ARFS - recurrence beyond salvage with intravesical therapy or RC), and overall survival (OS - death from any cause) via log-rank and Cox regression. Results Thirty six patients underwent NC and PC. Median age and follow up for the cohort were 69.7 yrs (IQR 58.8-76.8) and 16.8 mo (IQR 9.3-38.7). All tumors were solitary and < 5cm. Pre-NC, 22 (61%) were cT2, 21 (58%) had CIS, and 6 (17%) had N+. Post-NC, 21 (58%) were cT0, 5 (14%) had CIS, and 4 (11%) had N+. PC pathologic findings were pT0 in 18 (50%), CIS in 14 (39%), N+ in 4 (11%), and SM+ in 3 (8%). Of the post-NC 21 cT0, 7 (33%) had residual bladder disease at PC. At last follow up, 22 (61%) patients had intact bladder, 15 were with no evidence of disease (NED) and had no recurrences, 4 NED but had bladder recurrences salvaged by intravesical BCG (2) or RC (2), 1 NED after irradiation of brain metastasis. Four were alive with disease in the pelvis (2) and retroperitoneum (2). Of pts with known follow-up (n=35), 10 died of disease (1 had preventable death) at a median of 17.5 mo (IQR 11.3-37.5) and 1 died of other cause. Five year RFS, ARFS and OS were 28 %, 51%, and 63% respectively (figure). On multivariable analysis, the presence of post-NC N+ was associated with worse RFS (HR 14.5, p=0.048) and SM+ was associated with worse RFS (HR 6.7, p=0.02), ARFS (HR 6.0, p=0.04) and OS (HR 6.7, p=0.047). Conclusions PC with NC provides acceptable oncologic outcomes in highly selected patients with muscle invasive bladder cancer. Positive surgical margin at the time of PC is independently associated with worse RFS, ARFS and OS. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e556 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Wassim Bazzi More articles by this author Ryan Kopp More articles by this author Timothy Donahue More articles by this author Melanie Bernstein More articles by this author Paul Russo More articles by this author Bernard Bochner More articles by this author Sherri Donat More articles by this author Guido Dalbagni More articles by this author Harry Herr More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ..." @default.
• W1988637640 created "2016-06-24" @default.
• W1988637640 creator A5004320043 @default.
• W1988637640 creator A5015695327 @default.
• W1988637640 creator A5030709443 @default.
• W1988637640 creator A5031667361 @default.
• W1988637640 creator A5048541532 @default.
• W1988637640 creator A5063441120 @default.
• W1988637640 creator A5067271492 @default.
• W1988637640 creator A5072314299 @default.
• W1988637640 creator A5086957919 @default.
• W1988637640 date "2014-04-01" @default.
• W1988637640 modified "2023-09-27" @default.
• W1988637640 title "MP55-04 PARTIAL CYSTECTOMY POST NEOADJUVANT CHEMOTHERAPY: MEMORIAL SLOAN-KETTERING CANCER CENTER CONTEMPORARY EXPERIENCE" @default.
• W1988637640 doi "https://doi.org/10.1016/j.juro.2014.02.1552" @default.
• W1988637640 hasPublicationYear "2014" @default.
• W1988637640 type Work @default.
• W1988637640 sameAs 1988637640 @default.
• W1988637640 citedByCount "1" @default.
• W1988637640 countsByYear W19886376402016 @default.
• W1988637640 crossrefType "journal-article" @default.
• W1988637640 hasAuthorship W1988637640A5004320043 @default.
• W1988637640 hasAuthorship W1988637640A5015695327 @default.
• W1988637640 hasAuthorship W1988637640A5030709443 @default.
• W1988637640 hasAuthorship W1988637640A5031667361 @default.
• W1988637640 hasAuthorship W1988637640A5048541532 @default.
• W1988637640 hasAuthorship W1988637640A5063441120 @default.
• W1988637640 hasAuthorship W1988637640A5067271492 @default.
• W1988637640 hasAuthorship W1988637640A5072314299 @default.
• W1988637640 hasAuthorship W1988637640A5086957919 @default.
• W1988637640 hasConcept C121608353 @default.
• W1988637640 hasConcept C126322002 @default.
• W1988637640 hasConcept C141071460 @default.
• W1988637640 hasConcept C143998085 @default.
• W1988637640 hasConcept C2775910329 @default.
• W1988637640 hasConcept C2776694085 @default.
• W1988637640 hasConcept C2778292576 @default.
• W1988637640 hasConcept C2780352672 @default.
• W1988637640 hasConcept C530470458 @default.
• W1988637640 hasConcept C61434518 @default.
• W1988637640 hasConcept C71924100 @default.
• W1988637640 hasConceptScore W1988637640C121608353 @default.
• W1988637640 hasConceptScore W1988637640C126322002 @default.
• W1988637640 hasConceptScore W1988637640C141071460 @default.
• W1988637640 hasConceptScore W1988637640C143998085 @default.
• W1988637640 hasConceptScore W1988637640C2775910329 @default.
• W1988637640 hasConceptScore W1988637640C2776694085 @default.
• W1988637640 hasConceptScore W1988637640C2778292576 @default.
• W1988637640 hasConceptScore W1988637640C2780352672 @default.
• W1988637640 hasConceptScore W1988637640C530470458 @default.
• W1988637640 hasConceptScore W1988637640C61434518 @default.
• W1988637640 hasConceptScore W1988637640C71924100 @default.
• W1988637640 hasIssue "4S" @default.
• W1988637640 hasLocation W19886376401 @default.
• W1988637640 hasOpenAccess W1988637640 @default.
• W1988637640 hasPrimaryLocation W19886376401 @default.
• W1988637640 hasRelatedWork W1987461627 @default.
• W1988637640 hasRelatedWork W2125696407 @default.
• W1988637640 hasRelatedWork W2386417211 @default.
• W1988637640 hasRelatedWork W2401969674 @default.
• W1988637640 hasRelatedWork W2603025253 @default.
• W1988637640 hasRelatedWork W2954147811 @default.
• W1988637640 hasRelatedWork W2980761415 @default.
• W1988637640 hasRelatedWork W3129080622 @default.
• W1988637640 hasRelatedWork W4229366546 @default.
• W1988637640 hasRelatedWork W4315628570 @default.
• W1988637640 hasVolume "191" @default.
• W1988637640 isParatext "false" @default.
• W1988637640 isRetracted "false" @default.
• W1988637640 magId "1988637640" @default.
• W1988637640 workType "article" @default.